OxyPharma

OxyPharma AB, Box 47041, S-100 74 Stockholm, Sweden. Visiting address: Nybohovsbacken 23-25.
info@oxypharma.com, tel +46 (0)8 726 17 02, fax +46 (0)8 18 28 03.

OxyPharma is a Swedish privately held drug discovery
company developing new drugs primarily for the treatment
of Rheumatoid Arthritis (RA) and Multiple Sclerosis (MS). In
1998, based on preclinical results from the Company’s lead
compound B-220, studies were initiated to investigate its
effect in inflammatory and autoimmune disease models
for RA and MS.

Read more ››

OxyPharma's compounds are small molecules targeted for oral administration, differentiating the Company's potential therapies from almost all existing RA and MS therapies and most RA and MS drugs in late stage clinical development.

Read more ››

2009-06-01
Swedish drug development company OxyPharma has received approvals in both the USA and in Russia for a patent that covers Rabeximod, the company’s drug for the treatment of Rheumatoid Arthritis (RA) which is currently undergoing Phase II clinical studies.